ALD-R491

ALD-R491 is a first-in-class small molecule vimentin inhibitor developed by Aluda Pharmaceuticals. It targets the intermediate filament protein vimentin, which plays a key role in cell adhesion, motility, and immune regulation. By binding to vimentin, ALD-R491 modulates its structural dynamics and function without altering its expression levels. This leads to inhibition of endocytosis, endosomal trafficking, exosome release, and viral entry into cells. The drug also activates regulatory T cells (Tregs), suppresses overactive immune responses by releasing Tregs from their inactive state via vimentin modulation inside these cells, and blocks activation of the NLRP3 inflammasome implicated in inflammation[3][4][5][6]. Preclinical studies have shown efficacy in models of autoimmune diseases (such as inflammatory bowel disease), lung injury/fibrosis (including bleomycin-induced fibrosis), cancer invasion/metastasis through partial reversal of epithelial-to-mesenchymal transition phenotypes[1], and antiviral activity against SARS-CoV-2 infection[3][6]. ALD-R491 is orally bioavailable with a favorable safety profile.

Other names

(E)-1-(4-fluorophenyl)-3-(4-((4-morpholin-4-yl-6-styryl-1,3,5-triazin-2-yl)amino)phenyl)urea